|
 Bharat Biotech's data from clinical trials for Covaxin in the
age-group "has been thoroughly reviewed by the Central Drugs
Standard Control Organisation and Subject Expert Committee and
(they) have provided their positive recommendations," the vaccine
maker told Reuters in a statement.
The shot is also the second in the South Asian nation to get
approval for use among under 18 age-group, after Zydus Cadila's DNA
vaccine, though it is only approved for children aged 12 and above.
[to top of second column] |
 India has turned its focus
towards vaccinating children against the
coronavirus, having already rolled out more than
950 million doses to adults among its population
of nearly 1.4 billion.
(Reporting by Anuron Kumar Mitra in Bengaluru;
Editing by Arun Koyyur)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
